Overview
Dermatology Clinical Case Challenge: Can You Diagnose this Patient?
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
How are your diagnostic skills for identifying inflammatory skin conditions? In just 10 minutes, learners navigate through three real-world cases and respond to questions relative to possible next steps in diagnostic procedures considerate of each patient’s history and perspective, physical examination findings, lab results, and skin biopsy results. Diagnostic conclusions are revealed after reviewing all cases. Hear faculty insights on the implications of learner decisions along with rationales for appropriate next steps to aid in making a final diagnosis. Insights include evidence-based treatment strategies recommended for the patients according to the diagnoses. Take this opportunity to sharpen your diagnostic skills and improve the management of your patients!
This activity is intended for dermatologists and the multidisciplinary team who manage patients with inflammatory skin disorders.
Chronic inflammatory skin diseases are often responsible for significant disease burdens and impacts on quality of life related to pruritus and systemic comorbidities. Dermatology specialists play crucial roles in the recognition and diagnosis of these diseases, as well as identification of potential underlying systemic diseases. Dermatology specialists have been challenged to provide relief to patients with off-label therapies, but novel and emerging therapies may provide new opportunities to alleviate disease burden. To optimize care for patients with chronic inflammatory skin diseases, it is essential that all dermatology specialists be skillful in diagnosis and patient-centered management approaches and be knowledgeable about both current and emerging treatment strategies.
Upon completion of this activity, learners will be able to:
• Recognize inflammatory skin disorders and identify underlying dermatologic and systemic etiologies.
• Implement patient-centered management approaches that prioritize quality of life considerations for patients with inflammatory skin disorders.
• Evaluate novel and emerging strategies for the management of inflammatory skin disorders.
• Recognize inflammatory skin disorders and identify underlying dermatologic and systemic etiologies.
• Implement patient-centered management approaches that prioritize quality of life considerations for patients with inflammatory skin disorders.
• Evaluate novel and emerging strategies for the management of inflammatory skin disorders.
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an independent medical educational grant from Sanofi and Regeneron Pharmaceuticals.
Shawn Kwatra, MD
Associate Professor of Dermatology
Johns Hopkins University School of Medicine
Baltimore, MD
Associate Professor of Dermatology
Johns Hopkins University School of Medicine
Baltimore, MD
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Shawn Kwatra, MD
Sources of Funding for Research: Galderma, Incyte, Pfizer, Sanofi
Consulting Agreements: Abbvie, Amgen, Arcutis Biotherapeutics, Aslan Pharmaceuticals, Cara Therapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, Sanofi
Clinical Investigator: Galderma, Incyte, Pfizer, Sanofi
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Cannabinoids, kappa-opioid receptor antagonists, mu-opioid receptor antagonists, thalidomide, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants, gabapentinoids, neurokinin 1 receptor antagonists, topical capsaicin, topical ketamine, topical amitriptyline, topical lidocaine, Janus kinase inhibitors, mycophenolate mofetil, azathioprine, nemolizumab, cyclosporine, methotrexate, phototherapy, intralesional corticosteroids, topical calcipotriol, topical calcineurin inhibitors, topical corticosteroids, systemic corticosteroids, topical or systemic retinoic acid, topical tacrolimus, and topical pimecrolimus are not approved for the treatment of certain inflammatory skin conditions.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 45 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.
